Literature DB >> 30631586

Liquid biopsy guided precision therapy for lung cancers.

Chongrui Xu1, Michael Offin1, Paul K Paik1, Bob T Li1.   

Abstract

Entities:  

Year:  2018        PMID： 30631586      PMCID： PMC6297506          DOI： 10.21037/jtd.2018.11.02

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   3.005


× No keyword cloud information.
  13 in total

1.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Authors:  Yi-Long Wu; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Fumito Tsuji; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Sashi Nadanaciva; Rickard Sandin; Tony S Mok
Journal:  Lancet Oncol       Date:  2017-09-25       Impact factor: 41.316

Review 2.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Authors:  Jason D Merker; Geoffrey R Oxnard; Carolyn Compton; Maximilian Diehn; Patricia Hurley; Alexander J Lazar; Neal Lindeman; Christina M Lockwood; Alex J Rai; Richard L Schilsky; Apostolia M Tsimberidou; Patricia Vasalos; Brooke L Billman; Thomas K Oliver; Suanna S Bruinooge; Daniel F Hayes; Nicholas C Turner
Journal:  J Clin Oncol       Date:  2018-03-05       Impact factor: 44.544

3.  The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?

Authors:  Dorota Kwapisz
Journal:  Ann Transl Med       Date:  2017-02

4.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Authors:  Yi-Long Wu; Caicun Zhou; Cheng-Ping Hu; Jifeng Feng; Shun Lu; Yunchao Huang; Wei Li; Mei Hou; Jian Hua Shi; Kye Young Lee; Chong-Rui Xu; Dan Massey; Miyoung Kim; Yang Shi; Sarayut L Geater
Journal:  Lancet Oncol       Date:  2014-01-15       Impact factor: 41.316

5.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

6.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

7.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

Review 8.  Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.

Authors:  Michael Offin; Jacob J Chabon; Pedram Razavi; James M Isbell; Charles M Rudin; Maximilian Diehn; Bob T Li
Journal:  J Oncol       Date:  2017-03-14       Impact factor: 4.375

9.  EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

Authors:  Yi-Long Wu; Lecia V Sequist; Cheng-Ping Hu; Jifeng Feng; Shun Lu; Yunchao Huang; Wei Li; Mei Hou; Martin Schuler; Tony Mok; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Neil Gibson; Dan Massey; Miyoung Kim; James Chih-Hsin Yang
Journal:  Br J Cancer       Date:  2016-12-22       Impact factor: 7.640

10.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245
View more
  1 in total

1.  Can liquid biopsy-guided EGFR-targeted therapy be a surrogate for the tissue-based standard approach?

Authors:  In-Jae Oh
Journal:  Transl Lung Cancer Res       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.